Cognitive Rehabilitation for People With Cognitive Covid19
Long Covid19
About this trial
This is an interventional treatment trial for Long Covid19 focused on measuring cognitive rehabilitation, brain fog, Covid19
Eligibility Criteria
Inclusion Criteria: Aged between 30 and 60 years Evidence of prior CV19 infection: either positive CV19 PCR or positive CV19 antibody test or acute symptoms consistent with the recognised core features of acute CV19 infection and post-acute symptoms consistent with the recognised core features of long Covid Cognitive impairment persisting more than three months after the acute CV19 infection, defined in terms of subjective reports of cognitive decline post-infection Exclusion Criteria: Cognitive impairment prior to CV19 infection Occurrence of acute neurological disorder, such as stroke or encephalitis, that could give rise to cognitive sequelae People who are on any medications that are considered by the study investigators to have significant adverse effects on cognition A pre-existing major psychiatric or medical disorder that is considered by the study investigators to have potential to affect cognition High alcohol intake Recreational drug use Loss of mental capacity such that the affected individual is unable to give informed consent Participants will not be eligible for Workstream 2 if they do not exhibit significant impairment on baseline cognitive assessments, as they will not gain from cognitive rehabilitation. Participants with pacemakers or other implanted devices, those with metal foreign bodies (e.g. shrapnel from war injuries) and those who have had certain types of surgery will be excluded from the MRI substudy. Although MRI is not known to affect the unborn child, we will also exclude subjects who may be pregnant just to be on the safe side.
Sites / Locations
- University College LondonRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Intervention
Control
cognitive rehabilitation programme. 1h session per week x 10 weeks
The control group receives treatment as usual, this is, participants will carry on with the care they were receiving prior to entry in the study.